pharma · Coronary Artery Bypass Grafting · Hypertension Pulmonary Secondary · TENX
TENAX THERAPEUTICS
TENAX THERAPEUTICS, INC.
TENAX THERAPEUTICS is a pharma organization headquartered in Chapel Hill, USA. It trades on NYSE under ticker TENX. Primary therapeutic focus areas include Coronary Artery Bypass Grafting, Hypertension Pulmonary Secondar
Company details
- Status
- Public
- HQ
- Chapel Hill, USA
- Employees
- 19
- Programs
- 7
- Drugs
- 2
- Patents
- 4
TNX-103
Phase 3 · small molecule · Pulmonary Hypertension Associated With HFpEF
TNX-103 for Pulmonary Hypertension Associated With HFpEF is a Phase 3 program (small_molecule) at TENAX THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).
Internal code TNX-103-08
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- TENAX THERAPEUTICS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pulmonary Hypertension Associated With HFpEF
- Status
- active
- Trials
- 2